Entry into or termination of material definitive agreements (Items 1.01/1.02).
MVB FINANCIAL CORP entered into Credit Agreement with Raymond James Bank valued at $20,000,000 (effective 2026-02-24).
“On Febru ary 24, 2 026, MVB Financial Corp. (“MVB”) entered into a Credit Agreement (the “Credit Agreement”), with Raymond James Bank, a Florida-chartered bank (“Raymond James Bank”). Under the Credit Agreement, Raymond James Bank has extended to MVB a senior revolving line of credit in the principal amount of up to $20,000,000”
CYBERLOQ TECHNOLOGIES, INC. entered into a license with Relevate AI (effective 2026-02-26).
“On February 26, 2026, CyberloQ Technologies, Inc., a Nevada corporation (the “Company”) entered into an agreement with Relevate AI (“Relevate”) to integrate the features of CyberloQ® and its multi-factor security protocol into Relevate’s Platform as an authentication option.”
Metropolitan Bank Holding Corp. entered into Underwriting Agreement with UBS Securities LLC and Hovde Group, LLC as representatives of the underwriters named therein valued at approximately $169.3 million (effective 2026-02-25).
“On February 25, 2026, Metropolitan Bank Holding Corp. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with UBS Securities LLC and Hovde Group, LLC as representatives of the underwriters named therein (the “Underwriters”).”
MARA Holdings, Inc. entered into Strategic Agreement with Starwood Capital Group Global III, L.P. (effective 2026-02-26).
“On February 26, 2026, MARA USA Corporation (the “Company”), a wholly owned subsidiary of MARA Holdings, Inc. (“MARA”), entered into a Strategic Agreement (the “Strategic Agreement”) with Starwood Capital Group Global III, L.P. (“Starwood”) pursuant to which the Company and Starwood have agreed to, amongst other things, develop, lease and market a specified list of the Company’s existing bitcoin mining data centers”
PALVELLA THERAPEUTICS, INC. entered into Underwriting Agreement with TD Securities (USA) LLC, Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated valued at approximately $187.3 million (effective 2026-02-25).
“On February 25, 2026, Palvella Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated, as representatives (the “Representatives”) of the underwriters listed in Schedule A thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 1,600,000 shares (the “Firm Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), at a price to the public of $125.00 (the “Offering”).”
Insight Molecular Diagnostics Inc. entered into Specimen Collection Agreement with Quest Diagnostics Incorporated (effective 2026-02-20).
“On February 20, 2026, Insight Molecular Diagnostics Inc. (the “Company”) entered into a Specimen Collection Agreement (the “Agreement”) with Quest Diagnostics Incorporated (“Quest Diagnostics”).”
Vir Biotechnology, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc., as representatives of the several underwriters valued at approximately $141.1 million (effective 2026-02-25).
“On February 25, 2026, Vir Biotechnology, Inc. (Vir Bio) entered into an underwriting agreement (the Underwriting Agreement) with Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc., as representatives of the several underwriters named in Schedule I thereto (the Underwriters), in connection with the offer and sale by Vir Bio of 17,647,059 shares of common stock of Vir Bio, par value $0.0001 per share (Common Stock), at a price to the public of $8.50 per share (the Offering).”
Mayville Engineering Company, Inc. entered into Third Amendment with Wells Fargo Bank, National Association valued at $275,000,000 commitment of senior secured revolver (effective 2026-02-25).
“On February 25, 2026, Mayville Engineering Company, Inc. (the “Company”) entered into the Third Amendment (the “Third Amendment”) to its Amended and Restated Credit Agreement, dated as of June 28, 2023, by and among Mayville Engineering Company, Inc., certain subsidiaries of Mayville Engineering Company, as guarantors, the lenders from time-to-time party thereto, and Wells Fargo Bank, National Association, as Administrative Agent for the lenders”
ABBOTT LABORATORIES entered into Pricing Agreement with Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC valued at $20,000,000,000 aggregate principal amount (effective 2026-02-23).
“On February 23, 2026, Abbott Laboratories (“Abbott”) entered into a pricing agreement (the “Pricing Agreement”), dated February 23, 2026, by and among Abbott, Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC, for themselves and as representatives of the several other underwriters named therein (the “Underwriters”), pursuant to which Abbott agreed to issue and sell $20,000,000,000 aggregate principal amount of senior notes”
Kymera Therapeutics, Inc. terminated Open Market Sale Agreement SM with Jefferies LLC (effective 2026-02-26).
“On February 26, 2026, Jefferies LLC (“Jefferies”) acknowledged and accepted the Company’s prior written notice to terminate the Open Market Sale Agreement SM , dated as of October 31, 2024, by and between the Company and Jefferies, effective immediately.”
Kymera Therapeutics, Inc. entered into TD Cowen Sales Agreement with TD Securities (USA) LLC valued at up to $500,000,000 (effective 2026-02-26).
“On February 26, 2026, Kymera Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “TD Cowen Sales Agreement”), with TD Securities (USA) LLC (“TD Cowen”) with respect to an “at-the-market” offering program under which the Company may issue and sell, from time to time at the Company’s sole discretion, shares of the Company’s common stock, having an aggregate offering price of up to $500,000,000 (the “Shares”), through TD Cowen.”
Redwire Corp terminated Adams Street Credit Agreement with Adams Street Credit Advisors LP (effective 2026-02-20).
“On February 20, 2026, in connection with the Company’s repayment in full of all amounts outstanding under the Credit Agreement (the “Adams Street Credit Agreement”), dated as of October 28, 2020, by and among Redwire Holdings, LLC, the other borrowers, guarantors and lenders from time to time parties thereto, Adams Street Credit Advisors LP, as administrative agent and collateral agent and Adams Street Credit Advisors LP, as sole lead arranger and sole bookrunner, as subsequently amended, the Company terminated the Adams Street Credit Agreement in accordance with its terms.”
Redwire Corp amended Amended and Restated Credit Agreement with JPMorgan Chase Bank, N.A. valued at $90 million term loan and $30 million revolving facility (effective 2026-02-20).
“On February 20, 2026, Redwire Defense Tech Intermediate Holdings, LLC (“Parent”), a wholly owned subsidiary of Redwire Corporation (“Redwire” or the “Company”), entered into the Amended and Restated Credit Agreement (the “A&R Credit Agreement”) by and among Parent, Redwire Defense Tech Intermediate II Holdings, LLC (the “Lead Borrower”), the other borrowers from time to time party thereto (each a “Borrower” and collectively, the “Borrowers”), the guarantors from time to time party thereto, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent.”
Grindr Inc. entered into Cooperation Agreement with G. Raymond Zage, III valued at Standstill restrictions for 18 months, among other terms (effective 2026-02-26).
“On February 26, 2026, Grindr Inc. (the “Company” or “Grindr”) entered into a Cooperation Agreement (the “Cooperation Agreement”) with G. Raymond Zage, III, a member of the Board of Directors of the Company (the “Board”) and the Company’s largest stockholder.”
NUSCALE POWER Corp terminated Prior Sales Agreement (effective 2026-02-26).
“In connection with the entry into the Sales Agreement, the Company terminated its at-the-market offering program pursuant to its prior sales agreement, dated as of November 7, 2025 (the “Prior Sales Agreement”), between the Company and the sales agents named therein.”
NUSCALE POWER Corp entered into Sales Agreement with UBS Securities LLC, B. Riley Securities, Inc., Canaccord Genuity LLC, Tuohy Brothers Investment Research, Inc. valued at up to $1,000,000,000 (effective 2026-02-26).
“On February 26, 2026, NuScale Power Corporation (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with UBS Securities LLC (“UBS”), B. Riley Securities, Inc. (“B. Riley”), Canaccord Genuity LLC (“Canaccord”) and Tuohy Brothers Investment Research, Inc. (“Tuohy Brothers”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its Class A common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $1,000,000,000”
PureCycle Technologies, Inc. amended Series A Supplemental Warrant Agreement with Continental Stock Transfer & Trust Company (effective 2026-02-25).
“On February 25, 2026, the Company and the Warrant Agent entered into a supplemental agreement to that certain Warrant Agency Agreement, dated as of September 2, 2022 (the “Series A Supplemental Warrant Agreement”), between the Company and the Warrant Agent, in order to memorialize the foregoing amendments, which will be effective as of March 17, 2026.”
PureCycle Technologies, Inc. amended PCT Warrants Supplemental Warrant Agreement with Continental Stock Transfer & Trust Company (effective 2026-02-25).
“On February 25, 2026, PureCycle Technologies, Inc. (the “Company”) entered into a supplemental agreement (the “PCT Warrants Supplemental Warrant Agreement”) to that certain Warrant Agreement (the “Original PCT Warrant Agreement”), dated as of May 4, 2020, by and between Roth CH Acquisition I Co. (now known as PureCycle Technologies Holding Corp., a wholly owned direct subsidiary of the Company) and Continental Stock Transfer & Trust Company, as warrant agent”
NKGen Biotech, Inc. amended Alpine Fourth Amendment with AlpineBrook Capital GP I Limited valued at $343,000 (effective 2026-02-20).
“On February 20, 2026, NKGen Biotech, Inc. (the “Company”) and NKGen Operating Biotech, Inc., a Delaware corporation (together with the Company, the “Borrowers”), entered into a fourth amendment (the “Alpine Fourth Amendment”) to that certain secured promissory note with AlpineBrook Capital GP I Limited, dated January 5, 2026, as amended by that certain amendment to secured promissory note dated January 12, 2026, that certain amendment no. 2 to secured promissory note dated January 23, 2026, and that certain amendment no. 3 to secured promissory note dated January 30, 2026 (the “Note”). The Alpine Fourth Amendment provides an additional $343,000 of funding to the Borrowers (the “Fifth Additional New Loan”).”
Zoomcar Holdings, Inc. entered into Securities Purchase Agreements with the purchasers named therein valued at aggregate gross proceeds of approximately $939 (effective 2026-02-25).
“On February 25, 2026, Zoomcar Holdings, Inc. (the “Company”) consummated the closing (the “Closing”) of its previously announced private placement (the “Private Placement”) of common stock purchase warrants (the “Warrants”) pursuant to Securities Purchase Agreements (the “Securities Purchase Agreements”) entered into by and between the Company and the purchasers named therein (collectively, the “Purchasers”).”
TIGO ENERGY, INC. entered into Securities Purchase Agreement with certain institutional investors valued at $15 million (effective 2026-02-24).
“On February 24, 2026, Tigo Energy, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain institutional investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “ Offering ”), an aggregate of 5,000,000 shares of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), at a purchase price of $3.00 per share (the “ Shares ”), for gross proceeds from the Offering of $15 million, before deducting placement agent fee and estimated offering expenses.”
Zura Bio Ltd entered into Underwriting Agreement with Leerink Partners LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as representatives of the several underwriters valued at approximately $134.6 million (effective 2026-02-24).
“On February 24, 2026, Zura Bio Limited (the “ Company ’) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as representatives of the several underwriters listed therein (collectively, the “ Underwriters ”), pursuant to which the Company agreed to issue and sell 18,200,000 Class A ordinary shares”
Roadzen Inc. entered into Second Amendment to Securities Purchase Agreement and Junior Convertible Note with an institutional investor valued at Amendment to change installment dates to April 21, 2026 and May 21, 2026, and grant participation ri (effective 2026-02-25).
“On February 25, 2026, Roadzen Inc. (the “Company”) entered into a Second Amendment to Securities Purchase Agreement and Junior Convertible Note (the “Second Amendment”), which amended certain of the terms of (i) that certain Securities Purchase Agreement, dated as of November 20, 2025 (the “SPA”), entered into between the Company and an institutional investor (the “Investor”), and (ii) the junior convertible notes issued to the Investor in November 2025 (as previously amended, the “November Notes”) pursuant to the terms of the SPA, as described in the Current Report on Form 8-K filed by the Company on November 20, 2025.”
Sidus Space Inc. entered into Sales Agreement with ThinkEquity LLC (effective 2026-02-26).
“On February 26, 2026, Sidus Space, Inc. (the “Company”) entered into an ATM sales agreement (the “Sales Agreement”) with ThinkEquity LLC (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time (the “Offering”) through the Sales Agent, shares (the “Shares”) of the Company’s Class A common stock”
FTAI Infrastructure Inc. terminated Credit Agreement with BARCLAYS (effective 2026-02-25).
“On the Closing Date, the Company used the net proceeds from the Term Loans to repay in full all outstanding principal and interest (together with fees, expenses and other amounts owed in connection therewith) under the Credit Agreement, dated as of August 25, 2025, among the Company, the guarantors from time to time party thereto, the lenders from time to time party thereto and BARCLAYS, as administrative agent.”
FTAI Infrastructure Inc. entered into Term Loan Credit Agreement with Kennedy Lewis Investment Management LLC, Ares Management LLC and Caspian Capital LP valued at $1,314.6 million (effective 2026-02-25).
“On February 25, 2026 (the “ Closing Date ”), FTAI Infrastructure Inc. (the “ Company ”) entered into a credit agreement (the “ Term Loan Credit Agreement ”) among Alter Domus (US) LLC, as administrative agent (the “ Administrative Agent ”), and certain funds, investment vehicles or accounts managed or advised by Kennedy Lewis Investment Management LLC, Ares Management LLC and Caspian Capital LP.”
Technology & Telecommunication Acquisition Corp amended IMTA Amendment with Continental Stock Transfer & Trust Company (effective 2026-02-20).
“Continental Stock Transfer & Trust Company entered into an amendment, dated February 20, 2026, to the Investment Management Trust Agreement, dated January 14, 2022, by and between Continental Stock Transfer & Trust Company and TETE (the “ IMTA Amendment ”).”
NCR Atleos Corp entered into Agreement and Plan of Merger with The Brink’s Company (effective 2026-02-26).
“On February 26, 2026, NCR Atleos Corporation, a Maryland corporation (“ NCR Atleos ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), by and among NCR Atleos, The Brink’s Company, a Virginia corporation (“ Brink’s ”), Novus Merger Sub, Inc., a Maryland corporation and wholly owned subsidiary of Brink’s (“ Merger Sub I ”) and Novus Merger Sub II, LLC, a Maryland limited liability company and wholly owned subsidiary of Brink’s (“ Merger Sub II ”).”
Legato Merger Corp. III entered into Subscription Agreements with accredited investors valued at $113.3 million (effective 2026-02-26).
“On February 26, 2026, Legato and Einride entered into subscription agreements (“ Subscription Agreements ”) with accredited investors (collectively, the “ Investors ”), pursuant to which Einride will, substantially concurrently with, and contingent upon, the consummation of the Merger, sell an aggregate of 12,235,420 American depositary shares of Einride (“ ADSs ”), each representing one ordinary share of Einride (“ Ordinary Share ”), to the Investors for an aggregate purchase price of $113.3 million (the “ PIPE ”).”
Legato Merger Corp. III amended Amendment with Einride AB (effective 2026-02-26).
“III, a Cayman Islands exempted company (“ Legato ”), Einride AB, a limited liability company formed under the laws of Sweden (“ Einride ”), and Einride Cayman Sub Limited, a Cayman Islands exempted company and a direct, wholly-owned subsidiary of Einride (“ Merger Sub ”), entered into a Business Combination Agreement (as it may be further amended, modified or supplemented from time to time, the “ BCA ”).”
Legato Merger Corp. III entered into Business Combination Agreement with Einride AB (effective 2025-11-12).
“on November 12, 2025, Legato Merger Corp. III, a Cayman Islands exempted company (“ Legato ”), Einride AB, a limited liability company formed under the laws of Sweden (“ Einride ”), and Einride Cayman Sub Limited, a Cayman Islands exempted company and a direct, wholly-owned subsidiary of Einride (“ Merger Sub ”), entered into a Business Combination Agreement (as it may be further amended, modified or supplemented from time to time, the “ BCA ”).”
Bicara Therapeutics Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives (effective 2026-02-24).
“On February 24, 2026, Bicara Therapeutics Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives (the “Representatives”) of the underwriters named therein (the “Underwriters”)”
ContextLogic Holdings Inc. entered into Credit Agreement with US Salt Investors, LLC, US Salt Holdings, LLC, Wilmington Trust, National Association, and the Lenders.
“On the Closing Date, Holdings, as the initial borrower, entered into a Credit Agreement (as amended, restated, amended and restated, extended, supplemented or otherwise modified in writing from time to time, the “ Credit Agreement ”), with US Salt Investors, LLC, a Delaware limited liability company (the “ Borrower ”), as the borrower, US Salt Holdings, LLC, a Delaware limited liability company (“ US Salt Holdings ”), as holdings, the guarantors from time to time party thereto, Wilmington Trust, National Association, as administrative agent and collateral agent (the “ Agent ”), and each lender from time to time party thereto (the “ Lenders ”).”
ContextLogic Holdings Inc. amended Second Amended and Restated Limited Liability Company Agreement (effective 2025-03-06).
“As contemplated by the Purchase Agreement, on the Closing Date, Holdings entered into a Second Amended and Restated Limited Liability Company Agreement (the “ 2nd A&R LLCA ”) which amended and restated that certain Amended and Restated Limited Liability Company Agreement entered into on March 6, 2025, as previously disclosed.”
ContextLogic Holdings Inc. entered into Escrow Agreement with Wilmington Trust, NA, the Sellers Representative, and ContextLogic Holdings, LLC valued at $2,750,000.
“In connection with the Purchase Agreement, Wilmington Trust, NA, a national banking association (the “ Escrow Agent ”), the Sellers Representative (as defined below), and ContextLogic Holdings, LLC, a wholly-owned subsidiary of the Company (“ Holdings ”) entered into an escrow agreement (the “ Escrow Agreement ”) which sets forth the terms of the Escrow Fund (as defined below), which is to include the Escrow Amount of $2,750,000.”
ContextLogic Holdings Inc. entered into Voting Agreement with Abrams Capital Partners I, L.P., Abrams Capital Partners II, L.P., Riva Capital Partners V, L.P., Riva Capital Partners VI, L.P. (collectively, the 'Abrams Investors'), and BCP Special Opportunities Fund III Originations LP.
“In connection with entering into the Purchase Agreement, on the Closing Date, each of Abrams Capital Partners I, L.P., a Delaware limited partnership (“ ACP I ”), Abrams Capital Partners II, L.P., a Delaware limited partnership (“ ACP II ”), Riva Capital Partners V, L.P., a Delaware limited partnership (“ Riva V ”), and Riva Capital Partners VI, L.P., a Delaware limited partnership (“ Riva VI ”, and together with ACP I, ACP II and Riva V, collectively, the “ Abrams Investors ”), and BCP Special Opportunities Fund III Originations LP, a Delaware limited partnership (“ BCP ” and together with the Abrams Investors, the “ Voting Entities ”), entered into a voting agreement (the “ Voting Agreement ”).”
ARROW FINANCIAL CORP entered into Agreement and Plan of Merger with Adirondack Bancorp, Inc., Arrow Merger Sub, Inc. (effective 2026-02-25).
“On February 25, 2026, Arrow Financial Corporation, a New York corporation ("Arrow") entered into an Agreement and Plan of Merger (the “Agreement”) with Adirondack Bancorp, Inc., a New York corporation (“Adirondack”) and Arrow Merger Sub, Inc. (“Merger Sub”), a Maryland corporation and wholly owned subsidiary of Arrow.”
ITRON, INC. entered into Indenture with U.S. Bank Trust Company, National Association, as trustee (effective 2026-02-26).
“On February 26, 2026, the Company entered into an indenture with U.S. Bank Trust Company, National Association, as trustee, relating to the issuance by the Company of the Notes (the “Indenture”).”
ITRON, INC. entered into Purchase Agreement with J.P. Morgan Securities LLC, as representative of the several initial purchasers valued at $700.0 million principal amount of its 0.00% Convertible Senior Notes due 2032 (effective 2026-02-23).
“On February 23, 2026, Itron, Inc. (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) with J.P. Morgan Securities LLC, as representative of the several initial purchasers named therein (collectively, the “Initial Purchasers”), to issue and sell $700.0 million principal amount of its 0.00% Convertible Senior Notes due 2032 (the “Firm Notes”)”
BRINKS CO entered into Agreement and Plan of Merger with NCR Atleos Corporation, Novus Merger Sub, Inc., Novus Merger Sub II, LLC (effective 2026-02-26).
“On February 26, 2026, The Brink’s Company, a Virginia corporation (“ Brink’s ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), by and among Brink’s, NCR Atleos Corporation, a Maryland corporation (“ NCR Atleos ”), Novus Merger Sub, Inc., a Maryland corporation and wholly owned subsidiary of Brink’s (“ Merger Sub I ”) and Novus Merger Sub II, LLC, a Maryland limited liability company and wholly owned subsidiary of Brink’s (“ Merger Sub II ”).”
BOSTON SCIENTIFIC CORP entered into Term Loan Credit Agreement with Wells Fargo Bank, National Association, as administrative agent, and the several lenders party thereto valued at $6.000 billion (effective 2026-02-26).
“On February 26, 2026, the Company entered into a $6.000 billion term loan credit agreement (the “ Term Loan Credit Agreement ” and together with the 2026 Revolving Credit Agreement and the 364-Day Revolving Credit Agreement, the “ 2026 Credit Agreements ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent.”
BOSTON SCIENTIFIC CORP entered into 364-Day Revolving Credit Agreement with Wells Fargo Bank, National Association, as administrative agent, and the several lenders party thereto valued at $2.000 billion (effective 2026-02-26).
“On February 26, 2026, the Company entered into a $2.000 billion 364-day revolving credit agreement (the “ 364-Day Revolving Credit Agreement ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent.”
BOSTON SCIENTIFIC CORP entered into 2026 Revolving Credit Agreement with Wells Fargo Bank, National Association, as administrative agent, and the several lenders party thereto valued at $3.000 billion (effective 2026-02-26).
“On February 26, 2026, Boston Scientific Corporation (the “ Company ”) entered into a $3.000 billion revolving credit agreement (the “ 2026 Revolving Credit Agreement ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent.”
PPL Corp entered into Supplemental Indenture No. 20 (2039 RSNs) dated February 26, 2026 with The Bank of New York Mellon valued at Establishes terms of $1,000 principal amount 4.02% Remarketable Senior Notes due 2039 (effective 2026-02-26).
“including by Supplemental Indenture No. 19, establishing the terms of the 2034 RSNs and by Supplemental Indenture No. 20, establishing the terms of the 2039 RSNs, each dated as of February 26, 2026.”
PPL Corp entered into Supplemental Indenture No. 19 (2034 RSNs) dated February 26, 2026 with The Bank of New York Mellon valued at Establishes terms of $1,000 principal amount 4.02% Remarketable Senior Notes due 2034 (effective 2026-02-26).
“including by Supplemental Indenture No. 19, establishing the terms of the 2034 RSNs and by Supplemental Indenture No. 20, establishing the terms of the 2039 RSNs, each dated as of February 26, 2026.”
PPL Corp entered into Purchase Contract and Pledge Agreement dated February 26, 2026 with The Bank of New York Mellon valued at Stock purchase contracts and pledge of RSNs as collateral for Common Stock purchase obligations (effective 2026-02-26).
“The stock purchase contracts were issued pursuant to a Purchase Contract and Pledge Agreement dated as of February 26, 2026 (the "Purchase Contract and Pledge Agreement"), among the Company and The Bank of New York Mellon, as purchase contract agent, collateral agent, custodial agent and securities intermediary.”
PPL Corp entered into Underwriting Agreement dated February 23, 2026 with J.P. Morgan Securities LLC, BofA Securities, Inc., Morgan Stanley & Co. LLC, RBC Capital Markets, LLC valued at Issuance and sale of up to 23,000,000 Corporate Units at $50 each (effective 2026-02-23).
“On February 23, 2026, PPL Corporation (the "Company") and PPL Capital Funding, Inc. ("PPL Capital Funding") entered into an underwriting agreement (the "Underwriting Agreement") with the underwriters named in Section 3 thereto (the "Underwriters"), for whom J.P. Morgan Securities LLC, BofA Securities, Inc., Morgan Stanley & Co. LLC and RBC Capital Markets, LLC are acting as representatives, covering the issuance and sale of 20,000,000 equity units, initially in the form of corporate units (the "Corporate Units").”
BARNWELL INDUSTRIES INC entered into Sales Agreement with Roth Capital Partners, LLC valued at $50,000,000 (effective 2026-02-25).
“On February 25, 2026, Barnwell Industries, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Roth Capital Partners, LLC (the “Agent”), under which the Company may, from time to time, sell shares of the Company’s common stock having an aggregate offering price of up to $50,000,000 in “at the market” offerings through or to the Agent, as sales agent.”
ALEXANDRIA REAL ESTATE EQUITIES, INC. entered into Second Supplemental Indenture with U.S. Bank Trust Company, National Association valued at $750,000,000 (effective 2026-02-25).
“On February 25, 2026, Alexandria Real Estate Equities, Inc. (the “Company”) issued and sold $750,000,000 aggregate principal amount of the Company’s 5.25% Senior Notes due 2036 (the “Notes”) in a registered public offering pursuant to an effective shelf registration statement on Form S-3 on file with the Securities and Exchange Commission. The Notes are governed by the terms of an Indenture, dated as of February 13, 2025 (the “Base Indenture”), by and among the Company, as issuer, Alexandria Real Estate Equities, L.P., as guarantor (the “Guarantor”), and U.S. Bank Trust Company, National Association , as trustee (the “Trustee”), as supplemented by Supplemental Indenture No. 2, dated as of February 25, 2026 (the “Second Supplemental Indenture” and, together with the Base Indenture, the “Indenture”), by and among the Company, the Guarantor and the Trustee.”
CONSOLIDATED EDISON INC entered into Forward Sale Agreement with JPMorgan Chase Bank, National Association valued at 7,000,000 of Con Edison’s Common Shares (effective 2026-02-23).
“On February 23, 2026, Consolidated Edison, Inc. (“Con Edison”) entered into a forward sale agreement (the “Forward Sale Agreement”) with JPMorgan Chase Bank, National Association (the “Forward Purchaser”) relating to 7,000,000 of Con Edison’s Common Shares”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.